Comparison of the efficay and side effects of nebulized oral pulmicort and inhaler budesonide in patients with eosinophilic esophagitis

Investigation and comparison of the efficacy and side effects of only nebulized oral Pulmicort and only inhaled budesonide and diet with oral budesonide nebul in patients aged one to 18 years with eosinophilic esophagitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191211045703N1

Enrollment

Registered

2020-06-24

Start date

2020-02-04

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eosinophilic esophagitis. Eosinophilic esophagitis

Interventions

Intervention 1: Intervention group: nebulized oral pulmicort.Palmicortic is a drug containing budesonide and belongs to the corticosteroids, which are commonly used to reduce and prevent inflammation

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Pediatric patients with eosinophilic esophagitis consent form parents proton pump consumption Adherence to the treatment protocols of this study

Exclusion criteria

Exclusion criteria: history of systemic corticosteroids drugs using history of systemic underlying diseases Adrenal insufficiency history

Design outcomes

Primary

Measure	Time frame
The effect of oral Budesonide nebulizer on improving Eosinophilic Esophagitis. Timepoint: Patients in the oral Budesonide nebulizer group will receive 1 puff twice a day.If the effectiveness of the drug is not observed after 8 weeks, patients will receive 2 puffs twice a day.Then during weeks 4,12,8 and 16 patients will be followed up and examined. Method of measurement: At the beginning of the study and after the 16th week, patients will be re-examined for histological and tissue pathology, as well as blood eosinophil counts and cortisol examination by Enzyme-linked immunosorbent test at 8 a.m.There will also be a routine laboratory test, such as hematology and biochemistry.	—

Measure

Time frame

The effect of oral Budesonide nebulizer on improving Eosinophilic Esophagitis. Timepoint: Patients in the oral Budesonide nebulizer group will receive 1 puff twice a day.If the effectiveness of the drug is not observed after 8 weeks, patients will receive 2 puffs twice a day.Then during weeks 4,12,8 and 16 patients will be followed up and examined. Method of measurement: At the beginning of the study and after the 16th week, patients will be re-examined for histological and tissue pathology, as well as blood eosinophil counts and cortisol examination by Enzyme-linked immunosorbent test at 8 a.m.There will also be a routine laboratory test, such as hematology and biochemistry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNastaran Amiri

Iran University of Medical Sciences

drnastaranamiri@gmail.com+98 21 2222 2041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026